Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 5,826

Document Document Title
WO/2013/067639
The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuro...  
WO/2013/064585
Compositions comprising mechanosensitive ion channel blockers, such as gadolinium, or N-cadherin antagonists or connexin 43 inhibitors enable musculoskeletal fibroproliferative disorders, such as Dupuytren's and other fibromatosis and li...  
WO/2013/063536
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.  
WO/2013/057230
The present invention relates to whey protein micelles for use in the treatment and/or prevention of a condition linked to a reduced concentration of plasma amino acids in a patient. A further aspect of the invention is a meal replacemen...  
WO/2013/058194
Provided are a pharmaceutical product, a quasi-pharmaceutical product, a food, an animal food, and a material mixable thereto that have an excellent SRF signal activation effect and are highly safe. This SRF signal activating agent compr...  
WO/2013/059606
Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targe...  
WO/2013/057231
The present invention relates to a non-therapeutic use of whey protein micelles to enhance muscle protein synthesis in a subject. Further aspects of the invention are food compositions comprising whey protein micelles to be administered ...  
WO/2013/058229
Provided are a pharmaceutical product, a quasi-pharmaceutical product, a food, an animal food, and a material mixable thereto that are highly safe and have an excellent effect of, for example, increasing the amount of muscles. This agent...  
WO/2013/054866
The present invention provides an agent for preventing or treating HAM and containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as the active ingredient. The present invention also provides an agent for ameliorat...  
WO/2013/055385
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...  
WO/2013/055385
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...  
WO/2013/054866
The present invention provides an agent for preventing or treating HAM and containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as the active ingredient. The present invention also provides an agent for ameliorat...  
WO/2013/053795
The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its conse...  
WO/2013/055577
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.  
WO/2013/045962
The invention refers to the use of compound of formula I or an N-oxide of the compound of formula I or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention and/or t...  
WO/2013/049293
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.  
WO/2013/045380
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/045885
The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of ...  
WO/2013/045380
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/049289
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.  
WO/2013/046335
[Problem] In a non-aqueous patch containing lidocaine, the adhesive force of the preparation tends to lower with an increase in the content of lidocaine. To release an effective amount of lidocaine from a patch to the skin, it is a commo...  
WO/2013/043580
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/043580
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/039197
An adenosine analog noraristeromycin (NAM) represented by this formula and having a selective inhibitory activity against IκB kinase α is used as: a therapeutic agent against recurring castration-resistant prostate cancer; a contracept...  
WO/2013/039244
Provided is an agent for stimulating skeletal muscle regeneration in muscle disease or myopathy. The agent for stimulating skeletal muscle regeneration contains chondroitinase as the active ingredient and accelerates regeneration of musc...  
WO/2013/038740
The present invention provides: a method for treating muscular atrophy; and a method and a means both for promoting muscle hypertrophy. Specifically, the present invention provides a method for screening for a substance or factor capable...  
WO/2013/040417
Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucle...  
WO/2013/035047
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provid...  
WO/2013/035712
The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom ...  
WO/2013/036875
The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells ...  
WO/2013/030569
The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.  
WO/2013/030569
The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleoti...  
WO/2013/029431
Disclosed are tosylate salts of benzodiazepine derivatives, their polymorphic forms, preparation methods and uses thereof, in particular to a tosylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1 ,4]benzodiazepine...  
WO/2013/031749
The present invention addresses the problem of providing a physical activity promoter that includes lactic acid bacteria from the human gut and/or a treated product of such lactic acid bacteria, or a food product composition for promotin...  
WO/2013/026099
The present disclosure provides proteins comprising antibody antigen binding domains that bind to Fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia.  
WO/2013/024311
The invention refers to the use of an amidoxime derivative of formula (I) or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention and/or treatment of muscle atrophy.  
WO/2013/024898
The primary purpose of the present invention is to provide a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the present invention can include a heterocyclic compound represented by general formul...  
WO/2013/021891
The purpose of the present invention is to provide an amino-acid-containing composition for recovering from muscle fatigue. An amino-acid-containing composition for enhancing the recovery from muscle fatigue, which comprises the amino ac...  
WO/2013/022052
Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a ta...  
WO/2013/023104
A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthr...  
WO/2013/018695
To provide a heterocyclic compound which has an RORγt inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group; Q represents a bonding hand or ...  
WO/2013/017672
The invention discloses a mammal sestrin product applicable in muscle atrophy, as well as any recombinant construction (vectors) comprising this mammal sestrin. A non-human animal model of muscle cell hypertrophy is also disclosed. In pa...  
WO/2013/014565
The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. These salts may be formulated as pharmaceutical compositions....  
WO/2013/007003
Disclosed is the use of acetylacetic acid in preparing drugs for promoting the proliferation of skeletal-muscle cells, the skeletal-muscle cells being myoblasts, wherein the acetylacetic acid promotes the proliferation of the skeletal-mu...  
WO/2013/007663
The invention relates to compounds that act as selective glycogen synthase kinase 3 (GSK-3) ligands and can be used for the treatment of GSK-3-mediated diseases. The compounds of the invention act as glycogen synthase kinase 3 (GSK-3) in...  
WO/2013/002248
The purpose of the present invention is to provide: a novel compound which has an S1P lyase inhibitory activity and can induce the reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof; and a pharmaceutica...  
WO/2013/003593
The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70. In a preferred embodiment, the composition comprises...  
WO/2013/003641
This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one...  
WO/2012/177653
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscula...  
WO/2012/175379
The invention relates to a homeopathic composition for effectively treating and preventing back, sciatic, or lumbar pain. The composition includes Cuprum metallicum, Staphysagria, Ribes nigrum, and preferably includes Spigelia.  

Matches 101 - 150 out of 5,826